Breast Cancer

Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.

What is Breast Cancer?

Breast cancer develops in the breast tissues, primarily in the ducts (milk-carrying channels) or lobules (milk-producing glands). Ductal carcinoma (70-80%) includes ductal carcinoma in situ (DCIS, non-invasive) and invasive ductal carcinoma (IDC). Lobular carcinoma (10-15%) affects lobes, with invasive lobular carcinoma (ILC) spreading more diffusely. Inflammatory breast cancer (1-5%) is aggressive, blocking lymph vessels and causing skin changes. Triple-negative (TNBC, 10-15%) and HER2-positive (15-20%) subtypes are molecularly distinct. In 2025, breast cancer is the most common cancer in women, with approximately 300,000 new US cases annually, and rising incidence in younger women (<40).

Symptoms

Symptoms include a palpable lump or thickening (often painless), changes in breast size/shape, skin dimpling, nipple inversion, spontaneous nipple discharge (especially bloody), red/scaly/swollen skin on the breast, nipple, or areola, and peau d’orange (orange-peel-like skin texture, common in inflammatory breast cancer). Advanced disease may cause breast pain, weight loss, fatigue, bone pain (from metastases), or swollen lymph nodes (axillary). Symptoms may mimic benign cysts or mastitis, necessitating imaging and biopsy for confirmation.

Causes

Breast cancer results from genetic and epigenetic alterations, with key mutations in BRCA1/2 (5-10% of cases, higher in Ashkenazi Jewish populations), TP53, PTEN, or PIK3CA. Risk factors include older age (70% of cases over 50), family history (first-degree relatives double risk), prolonged estrogen exposure (early menarche, late menopause, nulliparity, hormone replacement therapy), obesity, alcohol, and radiation exposure. Protective factors include breastfeeding, physical activity, and chemoprevention (e.g., tamoxifen in high-risk groups). In 2025, multigene panels (e.g., Oncotype DX, MammaPrint) identify recurrence risk and guide therapy, with lifestyle and environmental factors increasingly linked to rising incidence.

Diagnosis

Diagnosis involves a clinical breast exam, patient history, and imaging: mammography (screening gold standard, detecting 80-90% of cancers), ultrasound for dense breasts or younger women, and MRI for high-risk patients or staging. Biopsy (fine-needle aspiration, core, or surgical) confirms malignancy, with immunohistochemistry assessing estrogen/progesterone receptors (ER/PR, positive in 70%), HER2 status, and Ki-67 proliferation index. Multigene assays predict recurrence risk. Blood tests (CA 15-3, CEA) monitor advanced disease. In 2025, AI-enhanced mammography improves detection by 15%, and liquid biopsies (ctDNA) aid recurrence monitoring.

Treatment

Treatment is tailored to stage, subtype, and patient factors. Early-stage (I-II) cancers use breast-conserving surgery (lumpectomy) with radiation or mastectomy (with/without reconstruction), achieving 90-95% local control. Adjuvant therapies include chemotherapy (anthracyclines, taxanes for high-risk), hormone therapy (tamoxifen, aromatase inhibitors for ER/PR+), and targeted therapy (trastuzumab, pertuzumab for HER2+). Advanced (stage III-IV) or TNBC cases use neoadjuvant chemotherapy, immunotherapy (pembrolizumab for PD-L1+ TNBC, 40% response), and novel ADCs (sacituzumab govitecan). Radiation palliates metastases. In 2025, light-activated therapies (e.g., photodynamic ‘smart bombs’) and radiopharmaceuticals (e.g., alpha-emitting conjugates) achieve 20-30% response in metastatic disease, with rituximab combinations enhancing HER2+ outcomes.

Future Outlook

In 2025, breast cancer’s 5-year survival is 90% overall, 99% for localized, 86% for regional, and 29% for metastatic disease. Advances in immunotherapy, ADCs, and precision medicine (e.g., CDK4/6 inhibitors like palbociclib) extend metastatic survival to 3-5 years in optimal cases. Research focuses on mRNA vaccines, AI-driven risk stratification, and therapies targeting tumor microenvironment. By 2030, these could increase overall survival to 95% and metastatic to 40%, with emphasis on early detection, resistance mechanisms, and equitable access to novel therapies.

Sources

The information for breast cancer is sourced from the National Cancer Institute’s “Breast Cancer Treatment (PDQ®)” for comprehensive details on understanding, symptoms, causes, diagnosis, and treatment; Breast Cancer Research Foundation’s “ASCO 2025 Breast Cancer News” for 2025 advancements and clinical trial updates; Susan G. Komen’s “What’s New in Breast Cancer” for awareness and therapeutic developments; Mayo Clinic’s “Mayo Clinic treats first person in the US with a novel radiopharmaceutical therapy for breast cancer” for radiopharmaceutical innovations; and University of California Riverside’s “Breast cancer treatment advances with light-activated ‘smart bomb’” for novel therapeutic approaches.